| FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy. | |
| | |
MedLine Citation:
|
PMID: 19509024 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Some cases of nephrotic syndrome in focal and segmental glomerulosclerosis (FSGS) are associated with a circulating factor, the FSGS permeability factor (FSPF). Galactose has a high affinity for FSPF, and experimental data suggest that it could reduce its activity. We describe the case of a 48-year-old male with a nephrotic syndrome found to be resistant to corticosteroids, immunosuppression and plasmaphaeresis. The patient was given oral galactose as a last resort treatment, which was followed by a remission of his nephrotic syndrome that correlated with a reduction of FSPF activity. This case is the first report of a long-standing remission of an FSPF-associated nephrotic syndrome on oral galactose therapy. |
| | |
Authors:
|
Eric De Smet; Jean-Philippe Rioux; Hélène Ammann; Clément Déziel; Serge Quérin |
Related Documents
:
|
7249424 - Nephrotic syndrome associated with lithium therapy. 14700154 - Intussusception associated with a relapsing nephrotic patient: a case report. 1251274 - The nephrotic syndrome in children. 7148754 - Nephrotic syndrome developed in the healing stage of necrotizing angiitis. 3111074 - Fatty and hemorrhagic liver and kidney syndrome in breeding hens caused by aflatoxin b1... 20453404 - Calcium-alkali syndrome-like symptoms manifested by daily alphacalcidol and thiazide. |
Publication Detail:
|
Type: Case Reports; Journal Article Date: 2009-06-09 |
Journal Detail:
|
Title: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association Volume: 24 ISSN: 1460-2385 ISO Abbreviation: Nephrol. Dial. Transplant. Publication Date: 2009 Sep |
Date Detail:
|
Created Date: 2009-08-18 Completed Date: 2009-12-01 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8706402 Medline TA: Nephrol Dial Transplant Country: England |
Other Details:
|
Languages: eng Pagination: 2938-40 Citation Subset: IM |
Affiliation:
|
Hôpital du Sacré-Coeur and Université de Montréal, QC, Canada. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Blood Proteins / metabolism* Creatinine / blood Galactose / administration & dosage*, therapeutic use Glomerulosclerosis, Focal Segmental / blood, complications Humans Male Middle Aged Nephrotic Syndrome / blood*, drug therapy*, etiology Proteinuria / blood, drug therapy, etiology |
| Chemical | |
Reg. No./Substance:
|
0/Blood Proteins; 26566-61-0/Galactose; 60-27-5/Creatinine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Regulation of the fibrosis and angiogenesis promoter SPARC/osteonectin in human adipose tissue by we...
Next Document: The impact of arteriovenous fistulas on aortic stiffness in patients with chronic kidney disease.